NCT01342484 - Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

placebo

comparison of different dosages of drug (low vs high) vs placebo

DRUG

BI1356 low dose

comparison of different dosages of drug (low vs high) vs placebo

DRUG

BI1356 high dose

comparison of different dosages of drug (low vs high) vs placebo

Trial Locations (25)

1218.56.01006 Boehringer Ingelheim Investigational Site, San Antonio

1218.56.01004 Boehringer Ingelheim Investigational Site, Norfolk

1218.56.11001 Boehringer Ingelheim Investigational Site, Montreal

1218.56.33003 Boehringer Ingelheim Investigational Site, Fort de France Cedex

1218.56.33006 Boehringer Ingelheim Investigational Site, Rouen

1218.56.50202 Boehringer Ingelheim Investigational Site, Guatemala City

1218.56.50203 Boehringer Ingelheim Investigational Site, Guatemala City

1218.56.39005 Boehringer Ingelheim Investigational Site, Florence

1218.56.52008 Boehringer Ingelheim Investigational Site, Chihuahua City

1218.56.52002 Boehringer Ingelheim Investigational Site, Guadalajara

1218.56.52001 Boehringer Ingelheim Investigational Site, León

1218.56.52003 Boehringer Ingelheim Investigational Site, Monterrey

1218.56.52004 Boehringer Ingelheim Investigational Site, Oaxaca City

1218.56.48002 Boehringer Ingelheim Investigational Site, Gdansk

1218.56.48001 Boehringer Ingelheim Investigational Site, Gliwice

1218.56.48004 Boehringer Ingelheim Investigational Site, Warsaw

1218.56.48003 Boehringer Ingelheim Investigational Site, Wroclaw

1218.56.70001 Boehringer Ingelheim Investigational Site, Moscow

1218.56.70003 Boehringer Ingelheim Investigational Site, Saratov

1218.56.70004 Boehringer Ingelheim Investigational Site, Ufa

1218.56.70006 Boehringer Ingelheim Investigational Site, Yekaterinburg

1218.56.82005 Boehringer Ingelheim Investigational Site, Busan

1218.56.82001 Boehringer Ingelheim Investigational Site, Seoul

1218.56.82002 Boehringer Ingelheim Investigational Site, Seoul

1218.56.82003 Boehringer Ingelheim Investigational Site, Suwon